Bicycle Therapeutics plc
BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5ā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.86
Price-3.74%
-$0.15
1Y
Price
Market Cap
$267.863m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-486.6%
EBITDA Margin-503.7%
Net Profit Margin-612.3%
Free Cash Flow Margin-486.6%
EBITDA Margin-503.7%
Net Profit Margin-612.3%
Free Cash Flow MarginRevenue
$61.205m
-19.7%
1y CAGR+32.5%
3y CAGR+30.3%
5y CAGREarnings
-$190.412m
-48.3%
1y CAGR-34.0%
3y CAGR-42.7%
5y CAGREPS
-$2.73
-24.5%
1y CAGR-5.1%
3y CAGR-14.4%
5y CAGRBook Value
$510.255m
$606.578m
Assets$96.323m
Liabilities$13.680m
DebtDebt to Assets
2.3%
-0.1x
Debt to EBITDAFree Cash Flow
-$205.592m
-45.9%
1y CAGR-55.8%
3y CAGR-173.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company